Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 2/20 | 0.51 |
| ▸ | GALR1 | P47211 | 2/20 | 0.51 |
| ▸ | PIM1 | P11309 | 14/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.45 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032027 | 0.85 | GABBR2 (0.57) | GALR2GALR1GABBR2GABBR1KDM4E | |
| SCHEMBL1034543 | 0.83 | GABBR2 (0.58) | GALR2GALR1GABBR2GABBR1KDM4E | |
| SCHEMBL1034396 | 0.81 | GABBR2 (0.55) | GALR2GALR1GABBR2GABBR1KDM4E | |
| SCHEMBL1035407 | 0.80 | FYN (0.55) | PIM1KDM4EGAA | |
| SCHEMBL1034610 | 0.79 | GALR2 (0.53) | GALR2GALR1KCNH2GABBR2GABBR1 | |
| SCHEMBL1034751 | 0.78 | AGER (0.48) | GALR2GALR1GABBR2GABBR1KDM4E | |
| SCHEMBL1031099 | 0.77 | GALR2 (0.52) | GALR2GALR1KCNH2GABBR2GABBR1 | |
| SCHEMBL15117121 | 0.76 | CASR (0.41) | PIM1KCNH2PIM2MAP4K1 | |
| SCHEMBL2672690 | 0.76 | MAP4K1 (0.47) | PIM1KCNH2PIM2FLT3MAP4K1 | |
| SCHEMBL6887143 | 0.75 | KDM4E (0.59) | FLT3KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
| WO-2011008931-A2 | ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | GALR2 4500/4885GALR1 4245/4885PIM1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.